Skip Navigation

Board of Directors

Dr. Shannon is the Chairman of the Board of Arvinas and a Venture Partner at Canaan Partners. He also serves on the boards of Canaan portfolio companies IDEAYA Biosciences, Nextcure, Spyryx Biosciences, Vivace Therapeutics, and VaxInnate Corporation.

Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine.

Dr. Shannon received his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University. He earned his medical degree from the University of Connecticut and has a B.A. in Chemistry from Amherst College.

Dr. Houston is President and Chief Executive Officer of Arvinas and has over 28 years of experience in the pharmaceutical industry. Prior to joining Arvinas, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. He was also the site head of the BMS Connecticut facility. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late stage clinical trials, and toward commercialization. He was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS which oversaw the design and implementation of an industry-leading integrated lead discovery and optimization process. This initiative created revolutionary changes in the discovery process at BMS with significant improvements in capacity, speed and cost control resulting in marked increases in research productivity and success rates. Before his time at BMS, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit.

Dr. Houston currently serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics and BioCT. He obtained his B.Sc degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. Dr. Houston also completed his post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.

Ted is a Partner and Member of the Health Care and Life Sciences practice of Epstein Becker Green, a national law firm. A regulatory attorney for over 20 years, Ted counsels health care companies on the legal, reimbursement, coding and coverage issues facing providers, payers and the life sciences industry. Ted has also been an active leader in health care policy and in the movement to expand equal rights and opportunities to people with disabilities, and serves as Board Chair of the American Association of People with Disabilities.

Ted received a J.D. from the University of Connecticut School of Law, an M.E.S. from the Yale School of Forestry and Environmental Studies, and a B.A. from Wesleyan University. From 2015 to 2019, Ted served as State Senator in the Connecticut General Assembly.

Linda Bain is Chief Financial Officer of Codiak Biosciences, Inc. Previously, Ms. Bain served as Chief Financial Officer of Avalanche Biotechnologies, where she led a successful initial public offering (IPO) and follow-on financing. Additionally, she served as Vice President of Finance, Business Operations, and Treasurer at bluebird bio, where she led a successful IPO and Series D financing.

Prior to bluebird bio, Ms. Bain held senior roles at Genzyme Corporation and was Vice President of Finance, Global Manufacturing and Operations, and Vice President of Finance, Genzyme Genetics. Earlier in her career she held senior roles at Fidelity Investments, AstraZeneca, and Deloitte & Touche.

Ms. Bain also currently serves on the Board of Directors of Autolus Therapeutics. Ms. Bain is a Certified Public Accountant and earned a Bachelor of Science in Accounting and Business Administration and an Honors degree in Accounting and Business Administration from the University of the Free State, Bloemfontein, South Africa.

Mr. Margus currently serves as Executive Chair of Cerevance, a clinical-stage drug development company that he co-founded and led as Chief Executive Officer from 2016 to April 2022, focused on pursuing novel targets for brain diseases. From 2009-2012, he served as co-founder and Chief Executive Officer of Envoy Therapeutics, which employed a unique technology to discover new compounds for brain diseases, and then sold the company to Takeda Pharmaceuticals. From 2000 to 2007, Mr. Margus was the co-founder and Chief Executive Officer of Perlegen Sciences, a leader in analyzing genetic variation that raised $257 million from investors, exceeded $100 million in revenues, and identified diagnostic markers for disease risk and drug response.

Mr. Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He currently serves on the Boards of Neurona Therapeutics, Presage Biosciences and the non-profit A-T Children’s Project. Additionally, he serves as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH.

Mr. Margus obtained his M.B.A. from Harvard Business School.

Dr. Morrison received his B.S. in biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. He did postdocs with Philip Leder at Harvard Medical School, and Lee Nadler at the Dana-Farber. He joined Merck & Co., Inc. in 1995, was appointed Head of Clinical Development at Pfizer in 2007, and became Head of Global Medicines Development and Chief Medical Officer at AstraZeneca in 2012. He is currently President, Head of R+D and a board member at Syndax Pharmaceuticals and an Executive Partner at MPM Capital.

Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from first-in-human trials through to global regulatory approvals. He is currently a board member of Werewolf and Repare Therapeutics and is an advisor to several other private biotechnology companies.

Ms. Norwalk provides strategic counsel to a wide spectrum of healthcare corporations and biotechnology companies. She works in the Washington, D.C. office of Epstein Becker Green, P.C. and serves as strategic counsel to Epstein Becker Green, P.C., EBG Advisors and National Health Advisor. She also serves as an advisor to private equity firms. She currently sits on the boards of directors of NuVasive, Endologix, Providence Services Corporation, Magellan Health and several privately held health care companies. Additionally, Ms. Norwalk sits on APCO Worldwide’s International Advisory Council.

Prior to her work as an advisor, Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS). She managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities, and other federal health care initiatives. For four years prior to that, she was the agency’s Deputy Administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, she practiced law in the Washington, D.C., office of Epstein Becker Green, where she advised clients on a variety of health policy matters. She also served in the first Bush Administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative.

Ms. Norwalk earned a juris doctor degree from the George Mason University School of Law, where she was a Dean’s Scholar and an editor of the George Mason Law Review. She earned a bachelor’s degree, cum laude, in economics and international relations from Wellesley College.

Dr. Smaldone Alsup currently serves as the Chief Scientific Officer and Chief Medical Officer for NDA Group. She brings experience driving programs through all stages of development to commercially successful product approvals. Laurie has nearly 30 years of experience in the pharmaceutical industry, helping companies develop accelerated commercialization and market access strategies in the U.S. and global markets. Her expertise is broadly focused across multiple therapeutic areas including cancer, HIV/AIDS, infectious diseases, rare diseases, and metabolic, neurologic, and immunologic disorders. She spent over 20 years at Bristol Myers Squibb in roles of increasing responsibility in clinical development, regulatory strategy, and corporate risk management. She currently serves on the boards of Blackberry Ltd., Kinnate Biopharma, Inc., Pardes Biosciences, Inc., and Theravance Biopharma.

Dr. Smaldone Alsup received her M.D. from the Yale School of Medicine and completed her residency in Internal Medicine at Yale New Haven Hospital and a fellowship in Medical Oncology at Yale.

Wendy Dixon, Ph.D., is Director for Incyte Corporation, Alkermes plc, bluebird bio, and Voyager Therapeutics. She previously served as a Director and Chair of Sesen Bio and as a Director for Ardea Biosciences, Furiex Pharmaceuticals, and Dentsply International. Additionally, she served as an Independent Director for Edimer Therapeutics, a private company. From 2001 to 2009, Dr. Dixon was Chief Marketing Officer & President of Global Marketing at Bristol-Myers Squibb, as well as a member of the CEO’s Executive Committee. Prior to this she served as Senior Vice President of Marketing for Merck & Co., Inc. Dr. Dixon also held senior vice president roles at West Pharmaceuticals, Osteotech, Inc., Centocor, Inc., and Smith Kline & French Pharmaceuticals.

Throughout her career in the pharmaceutical and biotechnology industry, Dr. Dixon has been responsible for building and leading organizations, and launching and growing more than 20 pharmaceutical products including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge, UK.

John Young most recently served as Group President and Senior Advisor to the Pfizer CEO prior to his retirement from Pfizer in mid-2022. Mr. Young has been a distinguished member of several boards over the years. He currently serves on the Boards of Johnson Controls International (JCI), Haleon PLC (HLN) and Imbria Pharmaceuticals. Mr. Young previously served on the Boards of European Federation of Pharmaceutical Industries Associations, The Biotechnology Innovation Organization, and the National Committee on United States-China Relations.

A scientist by training, Mr. Young has almost 35 years of experience, a majority of which were working with Pfizer, where he held several leadership positions across the organization. As Chief Business Officer, Mr. Young led a division that integrated all Strategy, Consulting, Business Development, Business Assessment, Portfolio & Decision Analysis, and the Patient & Health Impact reimbursement and access teams. He also played an integral role in the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine.

Prior to this role, Mr. Young was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Consumer Healthcare. Each business unit focused on developing innovative medicines and vaccines to make a meaningful difference to patients impacted by diseases with significant unmet need.

Mr. Young holds a B.Sc. in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.